These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 26807601)

  • 1. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
    Nardon C; Brustolin L; Fregona D
    Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex.
    Jain SS; Anderson CM; DiRienzo F; Taylor IR; Jain K; Guha S; Hoque N
    Chem Commun (Camb); 2013 Jun; 49(44):5031-3. PubMed ID: 23615723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
    Liu P; Jia J; Zhao Y; Wang KZ
    Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
    Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
    [No Abstract]   [Full Text] [Related]  

  • 5. Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.
    Nagy EM; Pettenuzzo A; Boscutti G; Marchiò L; Dalla Via L; Fregona D
    Chemistry; 2012 Nov; 18(45):14464-72. PubMed ID: 23012112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noble metal-dithiocarbamates precious allies in the fight against cancer.
    Nagy EM; Ronconi L; Nardon C; Fregona D
    Mini Rev Med Chem; 2012 Oct; 12(12):1216-29. PubMed ID: 22931593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative activity of dmoPTA-Ru(II) complexes against human solid tumor cells.
    Ríos-Luci C; León LG; Mena-Cruz A; Pérez-Roth E; Lorenzo-Luis P; Romerosa A; Padrón JM
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4568-71. PubMed ID: 21719285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
    Bergamo A; Gaiddon C; Schellens JH; Beijnen JH; Sava G
    J Inorg Biochem; 2012 Jan; 106(1):90-9. PubMed ID: 22112845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.
    Silva Dde O
    Anticancer Agents Med Chem; 2010 May; 10(4):312-23. PubMed ID: 20380636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes.
    Ronconi L; Fregona D
    Dalton Trans; 2009 Dec; (48):10670-80. PubMed ID: 20023894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
    Alessio E; Messori L
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
    Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
    J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoruthenium Complexes with C^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action.
    Novohradsky V; Yellol J; Stuchlikova O; Santana MD; Kostrhunova H; Yellol G; Kasparkova J; Bautista D; Ruiz J; Brabec V
    Chemistry; 2017 Nov; 23(61):15294-15299. PubMed ID: 28922506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium complexes can target determinants of tumour malignancy.
    Bergamo A; Sava G
    Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruthenium-based chemotherapeutics: are they ready for prime time?
    Antonarakis ES; Emadi A
    Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
    Groessl M; Zava O; Dyson PJ
    Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation.
    Wang X; Zhu D; Zhao C; He L; Du W
    Metallomics; 2015 May; 7(5):837-46. PubMed ID: 25856332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.